Osteoprotective Effects of ‘Anti-Diabetic’ Polyherbal Mixture in Type 1 Diabetic Rats
References
- 1. Bucala R, Vlassara H: Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 1995, 26(6):875-888.10.1016/0272-6386(95)90051-9
- 2. Wang J, Wang H: Oxidative stress in pancreatic beta cell regeneration. Oxid Med Cell Longev 2017, 2017:1930261.10.1155/2017/1930261556009628845211
- 3. International Diabetes Federation: IDF Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes Federation 2019. http://www.diabetesatlas.org
- 4. Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM, Luo SQ: Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-κB. Biochem Biophys Res Commun 2004, 314:197–207.10.1016/j.bbrc.2003.12.07314715266
- 5. King GL, Loeken MR: Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 2004. 22:333–338.10.1007/s00418-004-0678-915257460
- 6. Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, Pischon N, Trackman PC, Gerstenfeld L, Graves DT: Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007, 40:345–353.10.1016/j.bone.2006.09.011191320817064973
- 7. Hamada Y, Kitazawa S, Kitazawa R, Fujii H, Kasuga M, Fukagawa M: Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: A possible role of oxidative stress. Bone 2007, 40:1408–1414.10.1016/j.bone.2006.12.05717251074
- 8. Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P: Pentosidine effects on human osteoblasts in vitro, in: Annals of the New York Academy of Sciences Blackwell Publishing Inc 2008, 1126(1):166–172.10.1196/annals.1433.04418448811
- 9. Abbassy MA, Watari I, Soma K: The effect of diabetes mellitus on rat mandibular bone formation and microarchitecture. Eur J Oral Sci 2010, 118:364–369.10.1111/j.1600-0722.2010.00739.x20662909
- 10. Zhen D, Chen Y, Tang X: Metformin reverses the deleterious effects of high glucose on osteoblast function. J Diabetes Complications 2010, 24:334–344.10.1016/j.jdiacomp.2009.05.00219628413
- 11. Okazaki K, Yamaguchi T, Tanaka KI, Notsu M, Ogawa N, Yano S, Sugimoto T: Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis. Calcif Tissue Int 2012, 91:286–296.10.1007/s00223-012-9641-222903508
- 12. Zheng W, Wang S, Wang J, Jin F: Periodontitis promotes the proliferation and suppresses the differentiation potential of human periodontal ligament stem cells. Int J Mol Med 2015, 36:915–922.10.3892/ijmm.2015.2314456409026310866
- 13. Lebovitz HE:Diagnosis, classification, and pathogenesis of diabetes mellitus. J Clin Psychiatry 2001, 62:5–9.
- 14. Inzerillo AM, Epstein S:. Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord 2004, 5:261–268.10.1023/B:REMD.0000032415.83124.20
- 15. Duarte, V.M.G., Ramos, A.M.O., Rezende, L.A., Macedo, U.B.O., Brandão-Neto, J., Almeida, M.G., Rezende, A.A., 2005. Osteopenia: A bone disorder associated with diabetes mellitus. J Bone Miner Metab 23, 58–68.10.1007/s00774-004-0542-y15616896
- 16. Silva MJ, Brodt MD, Lynch MA, McKenzie JA, Tanouye KM, Nyman JS, Wang X: Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life. J Bone Miner Res 2009, 24:1618–1627.10.1359/jbmr.090316273093119338453
- 17. Herskind AM, Christensen K, Nørgaard-Andersen K, Andersen JF: Diabetes mellitus and healing of closed fractures. Diab Metab 1992, 18:63–64.
- 18. Forsén L, Meyer HE, Midthjell K, Edna TH: Diabetes mellitus and the incidence of hip fracture: Results from the Nord-Trondelag health survey. Diabetologia 1999, 42:920–925.10.1007/s00125005124810491750
- 19. Vestergaard P, Rejnmark L, Mosekilde L: Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009, 84:45–55.10.1007/s00223-008-9195-519067021
- 20. Vestergaard P: Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - A meta-analysis. Osteoporos Int 2007, 18:427–444.10.1007/s00198-006-0253-417068657
- 21. Hampson G, Evans C, Petitt RJ, Evans WD, Woodhead SJ, Peters JR, Ralston SH: Bone mineral density, collagen type 1 α 1 genotypes and bone turnover in premenopausal women with diabetes mellitus. Diabetologia 1998, 41:1314–1320.10.1007/s0012500510719833939
- 22. López-Ibarra P-J, Pastor MMC, Escobar-Jiménez F, Pardo MDS, González AG, Luna JDD, González AG, Requena MER, Diosdado MA:. Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. Endocr Pract 2001,. 7:346–351.10.4158/EP.7.5.34611585369
- 23. Mastrandrea LD, Wactawski-Wende J, Donahue RP, Hovey KM, Clark A, Quattrin T: Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care 2008, 31:1729–1735.10.2337/dc07-2426251833318591404
- 24. Kristin K, Nicodemus BA, Aaron R, Folsom MD: Type 1 and Type 2 Diabetes and Incident Hip Fractures in Postmenopausal Women. Epidemiology 2001, 24:1192–1197.10.2337/diacare.24.7.119211423501
- 25. Lim DW, Kim YT: Anti-osteoporotic effects of Angelica sinensis (Oliv.) Diels extract on ovariectomized rats and its oral toxicity in rats. Nutrients 2014, 6(10): 4362–4372.10.3390/nu6104362421092225325255
- 26. Parasuraman S, Thing GS, Dhanaraj SA: Polyherbal formulation: Concept of ayurveda. Pharmacogn Rev 2014, 8(16):73-80.10.4103/0973-7847.134229412782425125878
- 27. Han X, Yang Y, Metwaly AM, Xue Y, Shi Y, Dou D: The Chinese herbal formulae (Yitangkang) exerts an antidiabetic effect through the regulation of substance metabolism and energy metabolism in type 2 diabetic rats. J Ethnopharmacol 2019, 239:111942.10.1016/j.jep.2019.11194231075380
- 28. Künzle J: Herbs and weeds: A practical booklet on medicinal herbs Switzerland 1911.
- 29. Madić V, Stojanović-Radić Z, Jušković M, Jugović D, Žabar-Popović A, Vasiljević P:. Genotoxic and antigenotoxic potential of herbal mixture and five medicinal plants used in ethnopharmacology. South African J Bot 2019, 125:290–297.10.1016/j.sajb.2019.07.043
- 30. Madić V, Petrović A, Jušković M, Jugović D, Djordjević Lj, Stojanović G, Vasiljević P: Polyherbal mixture ameliorates hyperglycemia, hyperlipidemia and histopathological changes of pancreas, kidney and liver in a rat model of type 1 diabetes. J Ethnopharmacol 2021, 265:113210.10.1016/j.jep.2020.11321032795501
- 31. Liang W, Luo Z, Ge S, Li M, Du J, Yang M, Yan M, Ye Z, Luo Z: Oral administration of quercetin inhibits bone loss in rat model of diabetic osteopenia. Eur J Pharmacol 2011, 670:317–324.10.1016/j.ejphar.2011.08.01421914440
- 32. Abu Ayana MA, Elmasry NA, Shehata FI, Khalil NM: Efficiacy of quercetin on alveolar bone structure of rats with induced diabetes. Alexandria Dent J 2017, 42:141–146.10.21608/adjalexu.2017.57917
- 33. Banda M, Nyirenda J, Muzandu K, Sijumbila G, Mudenda S: Antihyperglycemic and Antihyperlipidemic Effects of Aqueous Extracts of Lannea edulis in Alloxan-Induced Diabetic Rats. Front Pharmacol 2018, 9-1099.10.3389/fphar.2018.01099617236030323764
- 34. Ay B, Parolia K, Liddell RS, Qiu Y, Grasselli G, Cooper DML, Davis JE: Hyperglycemia compromises Rat Cortical Bone by Increasing Osteocyte Lacunar Density and Decreasing Vascular Canal Volume. Commun Biol 2020, 3:20.10.1038/s42003-019-0747-1695240631925331
- 35. Mullender MG, Van Der Meer DD, Huiskes R, Lips P: Osteocyte density changes in aging and osteoporosis. Bone 1996, 18:109–113.10.1016/8756-3282(95)00444-0
- 36. Leite Duarte ME, da Silva RD: Histomorphometric analysis of the bone tissue in patients with non-insulin-dependent diabetes (DMNID). Rev Hosp Clin Fac Med 1996, 51:7–11.
- 37. Vashishth D, Gibson G, Kimura J, Schaffler MB, Fyhrie DP: Determination of bone volume by osteocyte population. Anat. Rec 2002, 267:292–295.10.1002/ar.10114
- 38. He Y, Mu C, Shen X, Yuan Z, Liu J, Chen W, Lin C, Tao B, Liu B, Cai K:Peptide LL-37 coating on micro-structured titanium implants to facilitate bone formation in vivo via mesenchymal stem cell recruitment. Acta Biomater 2018, 80:412-424.10.1016/j.actbio.2018.09.036
- 39. Tuukkanen J, Koivukangas A, Jämsä T, Sundquist K, MacKay CA, Marks SC: Mineral Density and Bone Strength Are Dissociated in Long Bones of Rat Osteopetrotic Mutations. J Bone Miner Res 2000, 15:1905–1911.10.1359/jbmr.2000.15.10.1905
- 40. Chauhan S, Sharma A, Upadhyay NK, Singh G, Lal UR, Goyal R: In-vitro osteoblast proliferation and in-vivo anti-osteoporotic activity of Bombax ceiba with quantification of Lupeol, gallic acid and β-sitosterol by HPTLC and HPLC. BMC Complement Altern Med 2018:18.10.1186/s12906-018-2299-1
- 41. Domazetovic V, Marcucci G, Pierucci F, Bruno G, Di Cesare Mannelli L, Ghelardini C, Brandi ML, Iantomasi T, Meacci E, Vincenzini MT: Blueberry juice protects osteocytes and bone precursor cells against oxidative stress partly through SIRT1. FEBS Open Bio 2019, 9:1082–1096.10.1002/2211-5463.12634
- 42. Zeiger E: Illusions of safety: antimutagens can be mutagens, and anticarcinogens can be carcinogens. Mutat Res / Reviews in Mutat Res 2003, 543:191–194.10.1016/S1383-5742(02)00111-4
- 43. Mody N, Parhami F, Sarafian TA, Demer LL: Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 2001, 31:509–519.10.1016/S0891-5849(01)00610-4
- 44. El-Tantawy WH, Al Haleem ENA: Therapeutic effects of stem cell on hyperglycemia, hyperlipidemia, and oxidative stress in alloxan-treated rats. Mol Cell Biochem. 2014, 391:193-200.10.1007/s11010-014-2002-x24604673
- 45. Fowlkes JL, Bunn RC, Thrailkill KM. Contributions of the insulin/insulin-like growth factor-1 axis to diabetic osteopathy. J Diabetes Metab. 2011, 1(3):S1-003.10.4172/2155-6156.S1-003359308723484069
- 46. Tsentidis C, Gourgiotis D, Kossiva L, et al. Higher levels of s- RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis. Osteoporos Int. 2016; 27:1631-1643.10.1007/s00198-015-3422-526588909
- 47. Shah VN, Harrall KK, Shah CS, et al. Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature. Osteoporos Int. 2017, 28:2601-2610.10.1007/s00198-017-4097-x28580510
- 48. Yano H, Ohya K, Amagasa T: Effects of Insulin on in vitro bone formation in fetal rat parietal bone. Endocr J. 1994, 41:293-300.10.1507/endocrj.41.2937951582
- 49. Cortizo AM, Sedlinsky C, McCarthy D, Blanco A, Schurman L: Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol. 2006, 536:38-4610.1016/j.ejphar.2006.02.03016564524
- 50. Mai QG, Zhang ZM, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem. 2011, 112:2902-2909.10.1002/jcb.2320621618594
- 51. Gao Y, Li Y, Xue J, Jia Y, Hu J: Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol. 2010, 635:231-263.10.1016/j.ejphar.2010.02.05120307532
- 52. Behera HN, Patnaik BK: Recovery from alloxan diabetes as revealed by collagen characteristics of bone, skin and tendon of Swiss Mice. Gerontology 1981, 27:32-36.10.1159/0002124467215817
- 53. Villarino ME, Sánchez LM, Bozal CB, Ubios AM: Influence of short-term diabetes on osteocytic lacunae of alveolar bone. A histomorphometric study. Acta Odontol Latinoam 2006, 19:23–28.
- 54. Molinuevo MS, Schurman L, McCarthy AD, Cortizo AM, Tolosa MJ, Gangoiti MV, Arnol V, Sedlinsky C: Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J J Bone Miner Res 2010, 25: 211-221.10.1359/jbmr.09073219594306
- 55. Spanheimer RG, Umpierrez GE, Stumpf V: Decreased collagen production in diabetic rats. Diabetes 1988, 37:371–376.10.2337/diab.37.4.3713378683
- 56. Pulido R, Bravo L, Saura-Calixto F: Antioxidant activity of dietary polyphenols as determined by a modified ferric reducing/antioxidant power assay. J Agric Food Chem 2000, 48:3396–3402.10.1021/jf991345810956123
- 57. Takebayashi J, Ishii R, Chen J, Matsumoto T, Ishimi Y, Tai A: Reassessment of antioxidant activity of arbutin: Multifaceted evaluation using five antioxidant assay systems. Free Radic. Res 2010, 44:473–478.10.3109/1071576100361076020166881
- 58. Jeszka-Skowron M, Krawczyk M, Zgoła-Grześkowiak A: Determination of antioxidant activity, rutin, quercetin, phenolic acids and trace elements in tea infusions: Influence of citric acid addition on extraction of metals. J Food Compos Anal 2015, 40:70-77.10.1016/j.jfca.2014.12.015
- 59. Frei B, Higdon JV: Antioxidant Activity of Tea Polyphenols In Vivo: Evidence from Animal Studies. J Nutr 2003, 133(10):3275S-3284S.10.1093/jn/133.10.3275S14519826
- 60. Oka Y, Iwai S, Amano H, Irie Y, Yatomi K, Ryu K, Yamada S, Inagaki K, Oguchi K: Tea Polyphenols Inhibit Rat Osteoclast Formation and Differentiation. J Pharmacol Sci 2011, 118(1):55-64.10.1254/jphs.11082FP32092838
- 61. Hasan W, Ahmad S, Thakur H, Abbas M: In vitro regulation of osteoclast generation: a cost-effective strategy to combat osteoporosis with natural antioxidants and polyphenols like EGCG. Eur J Acad Res 2014, 2:2286-4822.
- 62. Nicolin, V., De Tommasi, N., Nori, S.L., Costantinides, F., Berton, F., Di Lenarda, R., 2019. Modulatory Effects of Plant Polyphenols on Bone Remodeling: A Prospective View From the Bench to Bedside. Front Endocrinol (Lausanne). 10, 494.10.3389/fendo.2019.00494666399531396157
- 63. Jayachandrana M, Wua Z, Ganesana K, Khalidb S, Chunga SM, Xua B: Isoquercetin upregulates antioxidant genes, suppresses inflammatory cytokines and regulates AMPK pathway in streptozotocin-induced diabetic rats. Chem-Biol Interact 2019, 303:62-69.10.1016/j.cbi.2019.02.01730817903
- 64. Kyung TW, Lee JE, Shin HH, Choi HS: Rutin inhibits osteoclast formation by decreasing reactive oxygen species and TNF-α by inhibiting activation of NF-κB. Exp Mol Med 2008, 40:52–58.10.3858/emm.2008.40.1.52267932118305398
- 65. Fayeda HA, Barakata BM, Elshaerb SS, Abdel-Naimc AB, Menzed ET: Antiosteoporotic activities of isoquercitrin in ovariectomized rats: Role of inhibiting hypoxia inducible factor-1 alpha. Eur J Pharmacol 2019, 865: 172785.10.1016/j.ejphar.2019.17278531712059
- 66. Horcajada-Molteni MN, Crespy V, Coxam V, Davicco MJ, Rémésy C, Barlet JP: Rutin Inhibits Ovariectomy-Induced Osteopenia in Rats. JBMR 2000, 15:2251-2258.10.1359/jbmr.2000.15.11.225111092407
- 67. Yokoyama A, Sakakibara H, Crozier A, Kawai Y, Matsui A, Terao J, Kumazawa S, Shimoi K: Quercetin metabolites and protection against peroxynitrite-induced oxidative hepatic injury in rats. Free Radic Res 2009, 43:913-21.10.1080/1071576090313701019669999
- 68. Man X, Yang L, Liu S, Yang L, Li M, Fu Q: Arbutin promotes MC3T3-E1 mouse osteoblast precursor cell proliferation and differentiation via the Wnt/ß-catenin signaling pathway. Mol Med Rep 2019, 19:4637–4644.10.3892/mmr.2019.10125652280130957189
- 69. Prouillet C, Mazière J-C, Mazière C, Wattel A, Brazier M, Kamel S: Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. Biochem Pharmacol 2004, 67:1307–1313.10.1016/j.bcp.2003.11.00915013846
- 70. Kanter M, Altan MF, Donmez S, Ocakci A, Kartal ME: The effects of quercetin on bone minerals, biomechanical behavior, and structure in streptozotocin-induced diabetic rats. Cell Biochem Funct 2007, 25:747–752.10.1002/cbf.139717265531
- 71. Derakhshanian H, Ghadbeigi S, Rezaian M, Bahremand A, Javanbakht MH, Golpaie A, Hosseinzadeh P, Tajik N, Dehpour AR: Quercetin improves bone strength in experimental biliary cirrhosis. Hepatol Res 2013, 43:394–400.10.1111/j.1872-034X.2012.01075.x22882531
- 72. Omori A, Yoshimura Y, Deyama Y, Suzuki K: Rosmarinic acid and arbutin suppress osteoclast differentiation by inhibiting superoxide and NFATc1 downregulation in RAW 264.7 cells. Biomed Reports 2015, 3:483–490.10.3892/br.2015.452448701826171153
- 73. Barhoma RA, Hegab II, Atef MM, El-Shamy AM: Unraveling the Role of Melatonin/ Quercetin in Attenuating the Metabolic and Bone Turnover Alternations in Iron Treated-Ovariectomized Female Rats. Med J Cairo Univ 2019, 87:2857-2870.10.21608/mjcu.2019.59320
- 74. Chen Y, Dai F, He Y, Chen Q, Xia Q, Cheng G, Lu Y, Zhang Q: Beneficial effects of hyperoside on bone metabolism in ovariectomized mice. Biomed Pharmacother 2018, 107:1175–1182.10.1016/j.biopha.2018.08.06930257331
- 75. Qi X-C, Li B, Wu W-L, Liu, H-C, Jiang Y-P: Protective effect of hyperoside against hydrogen peroxide-induced dysfunction and oxidative stress in osteoblastic MC3T3-E1 cells. Artif Cells Nanomedicine Biotechnol 2020. 48, 377–383.10.1080/21691401.2019.170985131903787
- 76. Liu L, Wang D, Qin Y, Xu M, Zhou L, Xu W, Liu X, Ye L, Yue S, Zheng Q, Li D: Astragalin Promotes Osteoblastic Differentiation in MC3T3-E1 Cells and Bone Formation in vivo. Front Endocrinol (Lausanne) 2019, 10:228.10.3389/fendo.2019.00228647698431040823
- 77. Karadeniz F, Oh JH, Lee JI, Seo Y, Kong CS: 3,5-dicaffeoyl-epi-quinic acid from Atriplex gmelinii enhances the osteoblast differentiation of bone marrow-derived human mesenchymal stromal cells via WnT/BMP signaling and suppresses adipocyte differentiation via AMPK activation. Phytomedicine 2020, 71:153225.10.1016/j.phymed.2020.15322532464299
Language: English
Page range: 256 - 272
Accepted on: Jul 26, 2021
Published on: Sep 27, 2021
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2021 Aleksandra Petrović, Višnja Madić, Marina Jušković, Ljubiša Đorđević, Perica Vasiljević, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 License.